AbbVie vs Amgen
ABBV and AMGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABBV and AMGN compare
AbbVie is the larger company, worth 2.0 times as much as Amgen ($505B against $249B).
On earnings, Amgen is cheaper: it trades at 28.6× trailing earnings, against 80.8× for AbbVie.
AbbVie grew revenue faster over the last twelve months (10.4% versus 9.1% for Amgen).
Amgen keeps more of each dollar of sales as profit, with a net margin of 23.0% compared with 9.8% at AbbVie.
Both pay dividends: AbbVie yields 2.4% and Amgen 2.2%.
Amgen scores higher on the StockData Score (17 against 10 for AbbVie), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABBV | AMGN |
|---|---|---|
| Size and price | ||
| Market cap | $505B | $249B |
| Share price | $286.00 | $461.26 |
| Change, 1 year | 31.2% | 54.6% |
| Change, 5 years | 145% | 118% |
| Beta (5Y) | 0.28 | 0.41 |
| Employees | 57K | 32K |
| StockData Score | ||
| Total score | 10 | 17 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 | 5 (better) |
| Performance score | 2 | 6 (better) |
| Health score | 2 | 2 |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 80.8× | 28.6× (better) |
| P/S | 7.8× | 6.5× (better) |
| P/B | – | 21.3× |
| EV/EBITDA | 33.8× | 20.7× (better) |
| P/FCF | 27.8× | 24.5× (better) |
| PEG | – | 5.19 |
| FCF yield | 3.6% | 4.1% (better) |
| Fair value | $153.57 | $337.69 |
| Margin of safety | −86.2% | −36.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.4% (better) | 9.1% |
| Revenue growth, 5Y average | 6.0% | 7.6% (better) |
| Net income growth (TTM) | 67.7% (better) | 32.1% |
| EPS growth (TTM) | 68.6% (better) | 31.6% |
| EPS growth, 5Y average | −2.8% | 2.9% (better) |
| Profitability | ||
| Gross margin | 71.5% (better) | 69.5% |
| Operating margin | 26.2% | 30.0% (better) |
| Net margin | 9.8% | 23.0% (better) |
| FCF margin | 28.3% (better) | 26.7% |
| Return on equity | – | 91.5% |
| Return on invested capital | 20.1% (better) | 17.6% |
| Financial health | ||
| Debt / equity | – | 4.90 |
| Net debt / EBITDA | 3.81 | 3.07 (better) |
| Interest coverage | 5.8× (better) | 4.3× |
| Current ratio | 0.81 | 1.37 (better) |
| Altman Z-score | 2.79 (better) | 2.37 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Dividend yield | 2.4% (better) | 2.2% |
| Payout ratio | 190% | 60.4% |
| Years of dividend growth | 11 (better) | 9 |
| Dividend growth, 5Y average | 6.6% | 8.0% (better) |
| Buyback yield | 0.30% | – |
| Shareholder yield | 2.7% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 75.6% | 82.7% |
| Held by insiders | 0.09% | 0.21% |
| Insider net buying, 12 months | −$18.9M (better) | −$25.7M |
| Superinvestors holding | 3 | – |
| Short interest, % of float | 0.88% | 2.5% |
Go deeper
- ABBV stock overview
- ABBV income statement
- ABBV valuation and score
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
Other comparisons
- ABBV vs ABT
- ABBV vs BMY
- ABBV vs JNJ
- ABBV vs LLY
- ABBV vs PFE
- AMGN vs BIIB
- AMGN vs BMY
- AMGN vs GILD
- AMGN vs PFE
For information only, not investment advice. Check the source filings before relying on any figure.